Stockreport

Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) [Seeking Alpha]

Viridian Therapeutics, Inc.  (VRDN) 
PDF VRDN focuses on developing treatments for thyroid eye disease, and analyst firms project huge revenue and earnings growth in the coming years. The company has smartly [Read more]